Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Ezabenlimab + NK-92/5.28.z|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ezabenlimab||BI754091|BI-754091|BI 754091||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 109||Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).|
|NK-92/5.28.z||HER2.taNK|Anti-HER2-CAR-CD28zeta NK-92 Cells||NK-92/5.28.z are NK-92 natural killer cell line-derived cells engineered to express a chimeric antigen receptor (CAR) that targets ERBB2 (HER2) and contains CD28 and the signaling domain from CD3zeta, which potentially results in tumor cell cytotoxicity and inhibition of tumor growth (PMID: 28879551, PMID: 25373520).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03383978||Phase I||Ezabenlimab + NK-92/5.28.z||Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN)||Recruiting||DEU||0|